8 Biotechnology Stocks to Sell Now

Popular Posts: 7 “Triple A” Stocks to Buy7 Biotechnology Stocks to Buy Now16 Oil and Gas Stocks to Sell Now Recent Posts: 8 Biotechnology Stocks to Sell Now 7 Semiconductor Stocks to Sell Now 21 Commercial Banking Stocks to Buy Now View All Posts

This week, the overall grades of eight Biotechnology stocks are lower, according to the Portfolio Grader database. Each of these rates a “D” (“sell”) or “F” overall (“strong sell”).

Genomic Health, Inc. (NASDAQ:) is on the decline this week, earning a D (“sell”) after receiving a C (“hold”) last week. Genomic Health is a life science company, which is focused on the development and commercialization of genomic-based clinical diagnostic tests for cancer that allow physicians and patients to make individualized treatment decisions. In Portfolio Grader’s specific subcategory of Earnings Revisions, GHDX also gets an F. The stock price has fallen 10.6% over the past month, worse than the 1.3% decrease the Nasdaq has seen over the same period of time. .

The rating of Acorda Therapeutics, Inc. (NASDAQ:) slips from a C to a D. Acorda Therapeutics is a commercial stage biopharmaceutical company dedicated to the identification, development and commercialization of novel therapies that improve neurological function in people with multiple sclerosis (MS), spinal cord injury and other disorders of the central nervous system. The stock gets F’s in Earnings Revisions and Sales Growth. .

This week, Amarin Corporation Plc Sponsored ADR’s (NASDAQ:) rating worsens to a D from the company’s C rating a week ago. Amarin focuses on developing the treatment for cardiovascular disease in the field of lipid science. In Earnings Growth, Earnings Revisions, Equity, and Cash Flow the stock gets F’s. As of Oct. 16, 2013, 15.3% of outstanding Amarin Corporation Plc Sponsored ADR shares were held short. .

Exelixis, Inc. (NASDAQ:) earns an F (“strong sell”) this week, moving down from last week’s grade of D (“sell”). Exelixisis a development-stage biotechnology company dedicated to the discovery and development of small-molecule therapeutics for the treatment of cancer and other serious diseases. The stock receives F’s in Earnings Growth, Earnings Momentum, and Equity. Margin Growth and Sales Growth also get F’s. As of Oct. 16, 2013, 22.7% of outstanding Exelixis, Inc. shares were held short. .

This is a rough week for Trius Therapeutics, Inc. (NASDAQ:). The company’s rating falls to D from the previous week’s C. Trius Therapeutics is a biopharmaceutical company. The stock gets F’s in Earnings Growth, Earnings Momentum, and Equity. Cash Flow and Sales Growth also get F’s. .

Progenics Pharmaceuticals, Inc. (NASDAQ:) earns a D this week, falling from last week’s grade of C. Progenics Pharmaceuticals develops and distributes therapeutic products to treat the unmet medical needs of patients with debilitating conditions and life-threatening diseases. The stock gets F’s in Equity and Cash Flow. .

Discovery Laboratories, Inc.’s (NASDAQ:) rating weakens this week, dropping to a D versus last week’s C. Discovery Laboratories is a biotechnology company focused on developing products for the treatment of respiratory disease. The stock gets F’s in Equity and Cash Flow. .

The rating of Achillion Pharmaceuticals, Inc. (NASDAQ:) slips from a C to a D. Achillion focuses on the discovery, development and commercialization of innovative treatments for infectious diseases. The stock also rates an F in Equity. As of Oct. 16, 2013, 16.7% of outstanding Achillion Pharmaceuticals, Inc. shares were held short. .

Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.